Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Hedge fund Segantii Capital charged with insider trading
View:
Post by Noteable on May 08, 2024 12:37pm

Hedge fund Segantii Capital charged with insider trading

" The court documents show the case involves the long selling of 1.57mn listed securities in Esprit at an average execution price of HK$5.25 per share and the short selling of 132,000 of the shares at an average price of HK$5.23."

https://www.ft.com/content/be4d1b62-68c2-41c0-bb44-5a46dff962a6

https://www.bnnbloomberg.ca/segantii-allegations-roil-a-go-to-block-trader-for-global-banks-1.2069511
Comment by Noteable on May 08, 2024 1:03pm
The Segantii case adds to mounting scrutiny of block trading that has already swept up the likes of Morgan Stanley. In a landmark case in January, the Morgan Stanley agreed to pay $249 million to settle US accusations that employees leaked deals to favored funds that bet against — or “shorted” — shares before block trades. The bank benefited because those funds then served as ready buyers for the ...more  
Comment by Noteable on May 08, 2024 1:15pm
https://www.msn.com/en-us/money/companies/ex-segantii-trader-la-rocca-no-longer-joining-jpmorgan/ar-AA1o2Nlp
Comment by Noteable on May 08, 2024 1:21pm
Relatedly : -> https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?threadid=35270702
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse